Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended): A compound of Formula I:

A-B

~~its prodrug forms,~~ or pharmaceutically acceptable salts thereof, wherein

A represents ~~a saturated, unsaturated, or a partially unsaturated bicyclic heterocyclic ring structure substituted with R^6, R^7, R^8, R^9, and R^{20}~~



or



;

B represents



or



;

X and Y independently at each occurrence are selected from NH, N, C, or CH, such that at least one of X and Y always represents N or NH ; and

Z represents C or N; provided that, (i) when Z represents N, R^7 represents H or $C(=NH)NH_2$;

R^1 represents OH, halogen, COOH, $COO-C_{1-4}$ alkyl, $O-(CH_2)_{0-1}-Ph$, $N(R^{10})_2$, CH_2OR^{10}, C_{1-6} halogenated alkyl, $O-(CH_2)_{1-4}-CO-N(R^{10})_2$, SC_{1-4} alkyl, $NHSO_2C_{1-4}$alkyl, SO_2-OH, $O-SO_2-OH$, $O-SO_2-O-C_{1-4}$ alkyl, $OP(O)(OH)_2$, or ~~OPO_3C_{1-4} alkyl~~ $OP(O)(OH)OC_{1-4}$ alkyl;

R^2, R^3, R^4, and R^5 independently at each ~~occurance~~ occurrence represent H, SH, OR^{10}, halogen, $COOR^{10}$, $CONR^{11}R^{12}$, optionally substituted aryl, optionally substituted heterocyclyl, C_{4-14} cycloalkyl-C_{1-4} alkyl, C_{1-4} alkyl aryl, optionally substituted C_{1-14} straight chain, branched or cyclo alkyl, $O-(CH_2)_{2-6}-NR^{10}-(CH_2)_{0-3}-R^{24}$, $NR^{10}R^{24}$, $(CH_2)_{1-4}-NR^{33}R^{34}$, $(CH_2)_{1-4}-COOR^{33}$, $O-(CH_2)_{1-3}-CO$-het, $O-(CH_2)_{1-2}$-NH-CO-aryl, $O-(CH_2)_{1-2}-NR^{10}-CO-NR^{10}R^{33}$, $O-(CH_2)_{0-2}-C(O)-NR^{33}R^{34}$, $O-(CH_2)_{1-4}-COOR^{10}$, $O-(CH_2)_{1-3}$-het-R^{32}, O-optionally substituted cycloalkyl, $O-(CH_2)_{1-4}-NR^{10}$-COO-*t*-butyl, $O-(CH_2)_{1-4}-NR^{10}R^{33}$, $O-(CH_2)_{1-4}-NR^{10}-C(O)-C_{0-3}$-alkyl-optionally substituted aryl, O-substituted cycloalkyl, $O-(CH_2)_{0-6}$-optionally substituted aryl, $(CH_2)_{1-4}$-NH-$C(O)O-(CH_2)_{1-4}-PhR^{13}R^{14}$, NO_2, $O-(CH_2)_{0-4}-C(O)$-NH-tetrahydro carboline, $NR^{10}R^{28}$, $O-(CH_2)_{1-3}$-optionally substituted het, CH_2COOCH_3, $CH=CH-COOCH_3$, 5-amidino benzimidazole,



, or



;

alternatively R^2 and R^3 taken together form



;

R^6 and R^9 independently at each ~~occurance~~ occurrence represents H, halogen, cyano, C_{1-4} alkyl, C_{1-4} halogenated alkyl, NO_2, O-aryl or OR^{11};

R^7 and R^8 independently at each ~~occurance~~ occurrence represent OH, CF_3, H, NO_2, C_{1-4} alkyl, OC_{1-4} alkyl, ~~or~~ O-aryl, halogen, or cyano, or a basic group selected from guanidino, $C(=NH)N(R^{10})_2$, $C(=NH)$-NH-NH_2, $C(=O)NH_2$, 2-imidazoline, N-amidinomorpholine, N-amidino piperidine, 4-hydroxy-N-amidino piperidine, N-amidino pyrrolidine, tetrahydro pyrimidine, and thiazolidin-3-yl-methylideneamine; with the proviso that ~~only~~ one, but not both, of R^7 and R^8 represents a basic group;

R^{10} independently at each ~~occurance~~ occurrence represents H, $(CH_2)_{0-2}$-aryl, C_{1-4} halo alkyl, or C_{1-14} straight chain, branched or cyclo alkyl, and alternatively, when one atom is substituted with two R^{10} groups, the atom along with the R^{10} groups can form a five to 10 membered ring structure;

R^{11} and R^{12} independently at each ~~occurance~~ occurrence represent H or C_{1-4} alkyl;

R^{20} represents R^{24}, C_{1-4}-alkyl, $(CH_2)_{1-3}$-biphenyl, $(CH_2)_{1-4}$-Ph-$N(SO_2$-C_{1-2}-alkyl$)_2$, $(CH_2)_{1-4}$-NH-C(O)-R^{24}, $(CH_2)_{1-4}$-NH-SO_2-R^{24}, halogen, $COOR^{10}$, $(CH_2)_{1-4}$-Ph-$N(SO_2$-C_{1-2}alkyl), $(CH_2)_{1-4}$-NR^{10}-C(O)-R^{24}, $(CH_2)_{1-4}$-NR^{10}-SO_2-R^{24}, $(CH_2)_{1-4}$-het, $(CH_2)_{1-4}$-$CON(R^{10})_2$, $(CH_2)_{1-4}$-$N(R^{10})$-C(O)-$NR^{10}R^{24}$, $(CH_2)_{1-4}$-$N(R^{10})$-C(S)-$NR^{10}R^{24}$, or $(CH_2)_{1-3}$-COOH;

R^{24} represents R^{10}, $(CH_2)_{1-4}$-optionally substituted aryl, $(CH_2)_{0-4}OR^{10}$, CO-$(CH_2)_{1-2}$-$N(R^{10})_2$, $CO(CH_2)_{1-4}$-OR^{10}, $(CH_2)_{1-4}$-$COOR^{10}$, $(CH_2)_{0-4}$-$N(R^{10})_2$, SO_2R^{10}, COR^{10}, $CON(R^{10})_2$, $(CH_2)_{0-4}$-aryl-$COOR^{10}$, $(CH_2)_{0-4}$-aryl-$N(R^{10})_2$, or $(CH_2)_{1-4}$-het-aryl;

R^{28} represents $(CH_2)_{1-2}$-Ph-O-$(CH_2)_{0-2}$-het-R^{30}, C(O)-het, CH_2-Ph-CH_2-het-$(R^{30})_{1-3}$; $(CH_2)_{1-4}$-cyclohexyl-R^{31}, CH_2-Ph-O-Ph-$(R^{30})_{1-2}$, CH_2-(CH_2OH)-het-R^{30}, CH_2-Ph-O-cycloalkyl-R^{31}, CH_2-het-C(O)-CH_2-het-R^{30}, or CH_2-Ph-O-(CH_2)-O-het-R^{30};

R^{30} represents $SO_2N(R^{10})_2$, H, NHOH, amidino, or $C(=NH)CH_3$;

R^{31} represents R^{30}, amino-amidino, NH-$C(=NH)CH_3$ or R^{10};

R^{32} represents H, C(O)-CH_2-NH_2, or C(O)-$CH(CH(CH_3)_2)$-NH_2;

R^{33} and R^{34} independently at each ~~occurance~~ occurrence represent R^{10}, $(CH_2)_{0-4}$-Ar, optionally substituted aryl, $(CH_2)_{0-4}$ optionally substituted heteroaryl, $(CH_2)_{1-4}$-CN, $(CH_2)_{1-4}$-$N(R^{10})_2$, $(CH_2)_{1-4}$-OH, $(CH_2)_{1-4}$-SO_2-$N(R^{10})_2$; alternatively,

R^{33} and R^{34} along with the nitrogen atom that they are attached form ~~to forms~~ a 4 to 14 atom ring structure selected from tetrahydro-1H-carboline; 6,7-dialkoxyoxy-2-substituted 1,2,3,4-tetrahydro-isoquinoline,



or



;

R^{35} represents R^{10}, SO_2-R^{10}, COR^{10}, or $CONHR^{10}$;

E represents a bond, $S(O)_{0-2}$, O or NR^{10};

W_1, W_2, W_3 and W_4 independently represent C or N; and

Q, Q^1, Q^2, Q^3, L^1, L^2, L^3 and L^4 independently at each ~~occurance~~ occurrence represent N-natural or unnatural amino acid side chain, CHR^{10}, O, NH, $S(O)_{0-2}$, N-C(O)-NHR^{10}, SO_2-$N(R^{10})_2$, N-C(O)-NH-$(CH_2)_{1-4}$-R^{26}, NR^{10}, N-heteroaryl, N-C(=NH)-NHR^{10}, or N-$C(=NH)C_{1-4}$ alkyl;

R^{26} represents OH, NH_2, or SH;

provided that, (i) when R^1 = OH; R^7 = amidine; R^2, R^6, R^8, R^9, and R^{20} each represent H; and R^3, R^4, R^5 are independently chosen from H, CH_3, and halogen, then only one of R^3, R^4, and R^5 represents H; (ii) when R^1 = OH; R^7 = amidine; R^2, R^3, R^4, R^5, and R^{20} each represent

H; and R^6, R^8, R^9 are independently chosen from H, CH_3, and halogen, then only one of R^6, R^8, and R^9 represents H; (iii) at least two of W_1, W_2, W_3 and W_4 represent C and at least one of W_1, W_2, W_3 and W_4 represent N; and (iv) when R^1 = OH; R^7 = amidine; and R^2, R^3, R^4, R^5, R^6, R^8, and R^9, represent H, R^{20} cannot be CH_3.

2. (Canceled)

3. (Currently amended): A compound of Claim ~~2~~ 1 wherein

~~A represents~~



R^1 represents OH, O-Ph, COOH or $P(O)(OH)_2$;

R^7 represents ~~H, Br,~~ $CONH_2$, CN, C(=NH)-NH-NH_2, NH-C(=NH)-NH_2 or C(=NH)-NH_2;

R^{20} represents H, C_{1-2} alkyl, $(CH_2)_{1-4}$-optionally substituted aryl, $(CH_2)_{1-4}$-het; $(CH_2)_{1-4}$-$N(R^{10})_2$, $(CH_2)_{1-4}$-$CON(R^{10})_2$, $(CH_2)_{1-4}$-NR^{10}-C(O)-R^{24}, $(CH_2)_{1-4}$-NR^{10}-SO_2-R^{24}, or $(CH_2)_{1-3}$-COOH;

~~X and Y independently at each occurance are selected from NH, N, C, or CH, such that at least one of X and Y always represents N or NH ; and~~

~~Z represents C or N;~~

~~provided that, (i) when Z represents N, R^7 represents H or C(=NH)NH_2.~~

4. (Currently amended): A compound of claim 3 wherein

A represents



; ~~and~~ ;

B represents



, ~~and~~

X and Y represent N; and

R^7 represents -$CONH_2$, ~~or~~ or C(=NH)-NH_2 ~~;~~ .

5. (Currently amended): A compound of claim 4 wherein

R^1 represents OH, -COOH, ~~and~~ or O-$P(O)(OH)_2$;

R^2 and R^3 independently represent halogen, H, C_{1-4} alkyl, Ph, toluyl, OH, ~~O-$(CH_2)_{1-3}$-C(O)-NH-$(CH_2)_{1-2}$-CN~~ O-$(CH_2)_{1-2}$-C(O)-NH-$(CH_2)_{1-2}$-CN, O-$(CH_2)_{1-3}$-Ph-*p*-OCH_3, O-CH_2-C(O)-NH-$(CH_2)_{1-2}$-CH-$(CH_3)_2$, O-CH_2-C(O)-NH-(CH_2)-Ph, O-CH_2-C(O)-NH-(CH_2)-Ph-*p*CH_3, O-C_{1-3} alkyl, O-$(CH_2)_{0-2}$-Ph-R^{10}, O-CH_2-C(O)-NH-$(CH_2)_2$-H, Ph-C_{1-3} alkyl, Ph-$N(R^{10})_2$, O-$(CH_2)_{1-3}$-het, O-$(CH_2)_{1-3}$-Ph-halo, O-$(CH_2)_{1-3}$-$NHSO_2$Ph-R^{10}, O-$(CH_2)_{1-3}$-NHCO-$(CH_2)_{0-2}$-Ph, O-CH_2-C(O)-NH-CH_2-COO-$C(CH_3)_3$, O-$(CH_2)_2$-NHC(O)-CH_2-NH_2, -OPh, O-$(CH_2)_{1-3}$-NH-het, O-$(CH_2)_2$-NH-C(O)-pyridyl, O-$(CH_2)_2$-NH-C(O)-NH-benzyl, O-$(CH_2)_2$-cyclohexyl, O-$(CH_2)_2$-NH-C(O)-$(CH_2)_2$-$CONH_2$, O-$(CH_2)_2$-NH-C(O)-CH_2-OCH_3, thiophene, pyridyl or O-$(CH_2)_2$-pyridyl;

alternatively R^2 and R^3 taken together form



R^4 represents halogen, H, NO_2, C_{1-2}-alkyl, CH=CH-$COOCH_3$, $NHSO_2C_{1-2}$ alkyl, NHCO-het, $(CH_2)_{1-3}$-$COOR^{10}$, $(CH_2)_{1-3}$-CONH-$(CH_2)_{1-3}$-pyridyl, or $(CH_2)_{1-3}$-CONH-$(CH_2)_{1-3}$-dichlorophenyl;

R^5 represents H;

R^6 represents H;

R^7 represents C(=NH)-NH_2 or NH(=NH)NH_2;

R^8 represents H, halogen, OR^{10}, CF_3, or C(=NH)-NH_2;

R^9 represents H or halogen; and

R^{20} represents H.

6. (Canceled)

7. (Currently amended): A compound of claim ~~6~~ 5 wherein

R^1 represents OH, or COOH;

R^2 represents H, halogen, OH, phenyl, O-$(CH_2)_{1-3}$-Ph, imidazolyl, 5-amidino benzimidazolyl, O-$(CH_2)_{1-2}$-C(O)-NH-C_{1-6} alkyl, or O-CH_2-C(O)-NH-CH_2-Ph;

R^3 represents H, O-CH_2-COOH, O-CH_2-C(O)O-C_2H_5, O-CH_2-C(O)-NH-$(CH_2)_{1-4}$-aryl, O-$(CH_2)_{1-4}$-NH-C(O)-naphthyl, $CONH_2$, O-$(CH_2)_{1-2}$-C(O)N(R^{10})-$(CH_2)_{1-3}$-Ph-$R^{13}R^{14}$, O-CH_2-C(O)-N(R^{10})-CH_2-piperanyl, O-CH_2-C(O)-NH-CH_2-indoyl, $(CH_2)_{0-4}$-aryl,



,



,



[,]or



, or



;

R^4 represents H, $-CH_3$, halogen, $-OCH_3$,$-(CH_2)_{1-2}COOR^{10}$, -COOH, $-NO_2$, -OH, aryl,



R^5 represents H;

R^6 represents H;

R^7 represents ~~H, halogen,~~ -C(O)-NH_2, -C(=NH)-NH_2;

R^8 represents H, Cl, F, OH or OCH_3;

R^9 represents H; and

R^{13} and R^{14} independently at each ~~occurance~~ occurrence represents H, halogen, -OC_{1-2} alkyl, ~~-OH,~~ -CF_3, or -C_{1-4} alkyl; and

R^{15} represents H,


,

,

,

,

,

,

,

,

,

,

, or

; and

R^{20} represents H or $-CH_2-Ph$.

8. (Currently amended): A compound ~~of claim 2, wherein the compound is~~ selected from

3-[3-Bromo-5-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-4-hydroxy-phenyl]-N-phenethyl-propionamide;

3-[4-(6-Carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenyl]-N-(2,3-dichloro-benzyl)-propionamide;

2-[4-(6-Carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenoxy]-N-(2,3-dichloro-benzyl)-acetamide;

3-[3-Bromo-5-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-4-hydroxy-phenyl]-N-[2-(2,4-dichloro-phenyl)-ethyl]-propionamide;

3-[3-Bromo-5-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-4-hydroxy-phenyl]-N-(2-pyridin-2-yl-ethyl)-propionamide;

3-[3-Bromo-5-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-4-hydroxy-phenyl]-N-(3-phenyl-propyl)-propionamide;

2-[4-(6-Carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenoxy]-N -naphthalen-1-ylmethyl-acetamide;

2-(3'-Amino-5-chloro-2-hydroxy-biphenyl-3-yl)-3H-benzoimidazole-5-carboxamidine;

3-[3-Bromo-5-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-4-hydroxy-phenyl]-propionic acid;

2-(3,5-Bis-hydroperoxy-2-hydroxy-phenyl)-3H-benzoimidazole -5-carboxamidine;

2-[4-(5-Carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenoxy]-N-(3-chloro-benzyl)-acetamide;

N-Benzyl-3-[3-bromo-5-(6-carbamimidoyl-1H-benzoimidazol -2-yl)-4-hydroxy-phenyl]-propionamide;

2-(3,5-Dibromo-2,4-dihydroxy-phenyl)-3H-benzoimidazole-5-carboxamidine;

2-(2-Hydroxy-biphenyl-3-yl)-3H-benzoimidazole-5-carboxamidine;

2-(5-Chloro-2-hydroxy-biphenyl-3-yl)-3H-benzoimidazole-5-carboxamidine;

2-(2-Hydroxy-3-phenethyloxy-phenyl)-3H-benzoimidazole-5-carboxamidine;
N-(3-Bromo-benzyl)-2-[4-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenoxy]-acetamide;
2-{3-[1-(3-Amino-propionyl)-pyrrolidin-2-ylmethoxy]-2-hydroxy-phenyl}-3H-benzoimidazole-5-carboxamidine;
2-(5-Chloro-2-hydroxy-3-pyridin-3-yl-phenyl)-1H-benzoimidazole-5-carboxamidine;
2-[3-(5-Carbamimidoyl-1H-benzoimidazol-2-yl)-2-hydroxy-phenyl]-3,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-carboxamidine;
2-[3-(1-Aminoacetyl-pyrrolidin-2-ylmethoxy)-2-hydroxy-phenyl]-3H-benzoimidazole-5-carboxamidine; ~~and~~
2-(2-Hydroxy-3-phenoxy-phenyl)-3H-benzoimidazole-5-carboxamidine;
2-[2-Hydroxy-3-(1-methyl-1H-benzoimidazol-2-yl)-phenyl]-1H-benzoimidazole-5-carboxamidine;
2-[3-(1-Aminoacetyl-piperidin-3-ylmethoxy)-2-hydroxy-phenyl]-1H-benzoimidazole-5-carboxamidine;
2-{3-[1-(2-Amino-3-methyl-butyryl)-pyrrolidin-2-ylmethoxy]-2-hydroxy-phenyl}-1H-benzoimidazole-5-carboxamidine;
2-[2-Hydroxy-3-(1-hydroxyacetyl-pyrrolidin-2-ylmethoxy)-phenyl]-1H-benzoimidazole-5-carboxamidine;
2-(2-Hydroxy-5-iodo-3-methoxy-phenyl)-1H-benzoimidazole-5-carboxamidine;
2-{3-[1-(2-Amino-3-methyl-butyryl)-pyrrolidin-2-ylmethoxy]-2-hydroxy-phenyl}-3H-benzoimidazole-5-carboxamidine;
2-(2-Hydroxy-5-{4-[1-(1-imino-ethyl)-piperidin-4-yloxy]-benzylamino}-phenyl)-3H-benzoimidazole-5-carboxamidine; compound with methane;
2-(2-Hydroxy-5-{4-[1-(1-imino-ethyl)-piperidin-3-ylmethoxy]-benzylamino}-phenyl)-3H-benzoimidazole-5-carboxamidine;
2-(3-Bromo-2-hydroxy-5-methyl-phenyl)-3H-benzoimidazole-5-carboxamidine;

3-[2,6-Dibromo-4-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenoxy]-propionic acid;

3-[2,6-Dibromo-4-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenoxy]-propionic acid ethyl ester; and

2-[3-Bromo-2-hydroxy-5-(3-methoxy-but-3-enyl)-phenyl]-3H-benzoimidazole-5-carboxamidine;

or a stereoisomer or pharmaceutically acceptable salt form thereof.

9. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof.

10. (Canceled)

11. (Currently amended): A method for treating or preventing a ~~thromboembolic disorder~~ arterial thromboembolism, comprising administering to a patient in need thereof a therapeutically effective amount of a compound ~~according to Claim 2~~ having the formula:

A-B

or pharmaceutically acceptable salts thereof, wherein

A represents



;

B represents



X and Y independently at each occurrence are selected from NH, N, C, or CH, such that at least one of X and Y always represents N or NH ; and

Z represents C or N; provided that, (i) when Z represents N, R^7 represents H or $C(=NH)NH_2$;

R^1 represents OH, halogen, COOH, $COO\text{-}C_{1\text{-}4}$ alkyl, $O\text{-}(CH_2)_{0\text{-}1}\text{-}Ph$, $N(R^{10})_2$, CH_2OR^{10}, $C_{1\text{-}6}$ halogenated alkyl, $O\text{-}(CH_2)_{1\text{-}4}\text{-}CO\text{-}N(R^{10})_2$, $SC_{1\text{-}4}$ alkyl, $NHSO_2C_{1\text{-}4}$alkyl, SO_2-OH, O-SO_2-OH, O-SO_2-O-$C_{1\text{-}4}$ alkyl, $OP(O)(OH)_2$, or $OP(O)(OH)OC_{1\text{-}4}$ alkyl;

R^2, R^3, R^4, and R^5 independently at each occurrence represent H, SH, OR^{10}, halogen, $COOR^{10}$, $CONR^{11}R^{12}$, optionally substituted aryl, optionally substituted heterocyclyl, $C_{4\text{-}14}$ cycloalkyl-$C_{1\text{-}4}$ alkyl, $C_{1\text{-}4}$ alkyl aryl, optionally substituted $C_{1\text{-}14}$ straight chain, branched or cyclo alkyl, $O\text{-}(CH_2)_{2\text{-}6}\text{-}NR^{10}\text{-}(CH_2)_{0\text{-}3}\text{-}R^{24}$, $NR^{10}R^{24}$, $(CH_2)_{1\text{-}4}\text{-}NR^{33}R^{34}$, $(CH_2)_{1\text{-}4}\text{-}COOR^{33}$, $O\text{-}(CH_2)_{1\text{-}3}\text{-}CO\text{-het}$, $O\text{-}(CH_2)_{1\text{-}2}\text{-}NH\text{-}CO\text{-aryl}$, $O\text{-}(CH_2)_{1\text{-}2}\text{-}NR^{10}\text{-}CO\text{-}NR^{10}R^{33}$, $O\text{-}(CH_2)_{0\text{-}2}\text{-}C(O)\text{-}NR^{33}R^{34}$, $O\text{-}(CH_2)_{1\text{-}4}\text{-}COOR^{10}$, $O\text{-}(CH_2)_{1\text{-}3}\text{-het-}R^{32}$, O-optionally substituted cycloalkyl, $O\text{-}(CH_2)_{1\text{-}4}\text{-}NR^{10}\text{-}COO\text{-}t\text{-butyl}$, $O\text{-}(CH_2)_{1\text{-}4}\text{-}NR^{10}R^{33}$, $O\text{-}(CH_2)_{1\text{-}4}\text{-}NR^{10}\text{-}C(O)\text{-}C_{0\text{-}3}$-alkyl-optionally substituted aryl, O-substituted cycloalkyl, $O\text{-}(CH_2)_{0\text{-}6}$-optionally substituted aryl, $(CH_2)_{1\text{-}4}\text{-}NH\text{-}C(O)O\text{-}(CH_2)_{1\text{-}4}\text{-}PhR^{13}R^{14}$, NO_2, $O\text{-}(CH_2)_{0\text{-}4}\text{-}C(O)\text{-}NH$-tetrahydro carboline, $NR^{10}R^{28}$, $O\text{-}(CH_2)_{1\text{-}3}$-optionally substituted het, CH_2COOCH_3, $CH{=}CH\text{-}COOCH_3$, 5-amidino benzimidazole,



, or



;

alternatively R^2 and R^3 taken together form



,



or



;

R^6 and R^9 independently at each occurrence represents H, halogen, cyano, C_{1-4} alkyl, C_{1-4} halogenated alkyl, NO_2, O-aryl or OR^{11};

R^7 and R^8 independently at each occurrence represent OH, CF_3, H, NO_2, C_{1-4} alkyl, OC_{1-4} alkyl, O-aryl, halogen, or cyano, or a basic group selected from guanidino, $C(=NH)N(R^{10})_2$, $C(=NH)$-NH-NH_2, $C(=O)NH_2$, 2-imidazoline, N-amidinomorpholine, N-amidino piperidine, 4-hydroxy-N-amidino piperidine, N-amidino pyrrolidine, tetrahydro pyrimidine, and thiazolidin-3-yl-methylideneamine; with the proviso that one, but not both, of R^7 and R^8 represents a basic group;

R^{10} independently at each occurrence represents H, $(CH_2)_{0-2}$-aryl, C_{1-4} halo alkyl, or C_{1-14} straight chain, branched or cyclo alkyl, and alternatively, when one atom is substituted with two R^{10} groups, the atom along with the R^{10} groups can form a five to 10 membered ring structure;

R^{11} and R^{12} independently at each occurrence represent H or C_{1-4} alkyl;

R^{20} represents R^{24}, C_{1-4}-alkyl, $(CH_2)_{1-3}$-biphenyl, $(CH_2)_{1-4}$-Ph-$N(SO_2$-C_{1-2}-alkyl$)_2$, $(CH_2)_{1-4}$-NH-C(O)-R^{24}, $(CH_2)_{1-4}$-NH-SO_2-R^{24}, halogen, $COOR^{10}$, $(CH_2)_{1-4}$-Ph-$N(SO_2$-C_{1-2}alkyl), $(CH_2)_{1-4}$-NR^{10}-C(O)-R^{24}, $(CH_2)_{1-4}$-NR^{10}-SO_2-R^{24}, $(CH_2)_{1-4}$-het, $(CH_2)_{1-4}$-$CON(R^{10})_2$, $(CH_2)_{1-4}$-$N(R^{10})$-C(O)-$NR^{10}R^{24}$, $(CH_2)_{1-4}$-$N(R^{10})$-C(S)-$NR^{10}R^{24}$, or $(CH_2)_{1-3}$-COOH;

R^{24} represents R^{10}, $(CH_2)_{1-4}$-optionally substituted aryl, $(CH_2)_{0-4}OR^{10}$, CO-$(CH_2)_{1-2}$-$N(R^{10})_2$, $CO(CH_2)_{1-4}$-OR^{10}, $(CH_2)_{1-4}$-$COOR^{10}$, $(CH_2)_{0-4}$-$N(R^{10})_2$, SO_2R^{10}, COR^{10}, $CON(R^{10})_2$, $(CH_2)_{0-4}$-aryl-$COOR^{10}$, $(CH_2)_{0-4}$-aryl-$N(R^{10})_2$, or $(CH_2)_{1-4}$-het-aryl;

R^{28} represents $(CH_2)_{1-2}$-Ph-O-$(CH_2)_{0-2}$-het-R^{30}, C(O)-het, CH_2-Ph-CH_2-het-$(R^{30})_{1-3}$; $(CH_2)_{1-4}$-cyclohexyl-R^{31}, CH_2-Ph-O-Ph-$(R^{30})_{1-2}$, CH_2-(CH_2OH)-het-R^{30}, CH_2-Ph-O-cycloalkyl-R^{31}, CH_2-het-C(O)-CH_2-het-R^{30}, or CH_2-Ph-O-(CH_2)-O-het-R^{30};

R^{30} represents $SO_2N(R^{10})_2$, H, NHOH, amidino, or $C(=NH)CH_3$;

R^{31} represents R^{30}, amino-amidino, NH-$C(=NH)CH_3$ or R^{10};

R^{32} represents H, C(O)-CH_2-NH_2, or C(O)-$CH(CH(CH_3)_2)$-NH_2;

R^{33} and R^{34} independently at each occurrence represent R^{10}, $(CH_2)_{0-4}$-Ar, optionally substituted aryl, $(CH_2)_{0-4}$ optionally substituted heteroaryl, $(CH_2)_{1-4}$-CN, $(CH_2)_{1-4}$-$N(R^{10})_2$, $(CH_2)_{1-4}$-OH, $(CH_2)_{1-4}$-SO_2-$N(R^{10})_2$; alternatively;

R^{33} and R^{34} along with the nitrogen atom that they are attached form a 4 to 14 atom ring structure selected from tetrahydro-1H-carboline; 6,7-dialkoxyoxy-2-substituted 1,2,3,4-tetrahydro-isoquinoline,



or



;

R^{35} represents R^{10}, SO_2-R^{10}, COR^{10}, or $CONHR^{10}$;

E represents a bond, $S(O)_{0-2}$, O or NR^{10};

W_1, W_2, W_3 and W_4 independently represent C or N; and

Q, Q^1, Q^2, Q^3, L^1, L^2, L^3 and L^4 independently at each occurrence represent N-natural or unnatural amino acid side chain, CHR^{10}, O, NH, $S(O)_{0-2}$, N-C(O)-NHR^{10}, SO_2-$N(R^{10})_2$, N-C(O)-NH-$(CH_2)_{1-4}$-R^{26}, NR^{10}, N-heteroaryl, N-C(=NH)-NHR^{10}, or N-C(=NH)C_{1-4} alkyl;

R^{26} represents OH, NH_2, or SH;

provided that, (i) when R^1 = OH; R^7 = amidine; R^2, R^6, R^8, R^9, and R^{20} each represent H; and R^3, R^4, R^5 are independently chosen from H, CH_3, and halogen, then only one of R^3, R^4, and R^5 represents H; (ii) when R^1 = OH; R^7 = amidine; R^2, R^3, R^4, R^5, and R^{20} each represent H; and R^6, R^8, R^9 are independently chosen from H, CH_3, and halogen, then only one of R^6, R^8, and R^9 represents H; (iii) at least two of W_1, W_2, W_3 and W_4 represent C and at least one of W_1, W_2, W_3 and W_4 represent N; and (iv) when R^1 = OH; R^7 = amidine; and R^2, R^3, R^4, R^5,R^6, R^8,and R^9, represent H, R^{20} cannot be CH_3,[.]or a pharmaceutically acceptable salt thereof.

12. (Currently amended): A compound of Claim [2] 1 wherein A represents



;

B represents



X represents C; and

Y represents NH.

13. (Currently amended): A compound of claim 12 wherein

R^1 represents -OH, -COOH, or $P(O)(OH)_2$;

R^2 represents H, halogen, R^{10}, -aryl, heteroaryl, -C_{1-2}-alkyl, COOH, -OC_{1-2}-alkyl~~,~~ or -O-$(CH_2)_{0-2}$-aryl~~, or C_{6-10} aryl C_{1-4} alkyl~~;

R^3 represents H or -O-$(CH_2)_{1-3}$-COOH;

alternatively R^2 and R^3 taken together represent



R^4 represents H, C_{1-4} alkyl, -$(CH_2)_{1-4}$-COOH, -$(CH_2)_{1-4}$-$COOC_{1-2}$-alkyl, halogen, -$(CH_2)_{1-2}$-$CONH_2$, -$CONH_2$, -NO_2, -O-C_{1-2} alkyl, or -OH;

R^5 represents H, C_{1-3} alkyl~~, $(CH_2)_{1-4}$ C(O) NH $(CH_2)_{1-3}$ heteroaryl, $(CH_2)_{1-4}$ C(O) NH CH_3;~~ or -COOH;

R^6 represents H, halogen, or -C_{1-3} alkyl;

R^7 represents -C(O)-NH_2, -C(=NH)-NH-NH_2, or amidino;

R^8 represents H, or halogen; and

R^{20} represents H, -$(CH_2)_{1-4}$-Ph-N(SO_2-C_{1-2}alkyl), -$(CH_2)_{1-4}$-NR^{10}-C(O)-R^{24}, -$(CH_2)_{1-4}$-NR^{10}-SO_2-R^{24}, -$(CH_2)_{1-4}$-het, -$(CH_2)_{1-4}$-$CON(R^{10})_2$, -$(CH_2)_{1-4}$-$N(R^{10})$-C(O)-$NR^{10}R^{24}$, ~~$(CH_2)_{1-2}$ Ph~~

~~NH_2, $-(CH_2)_{1-2}$-Ph-NO_2,~~ $-(CH_2)_{1-4}$-$N(R^{10})$-C(S)-$NR^{10}R^{24}$, $-C_{1-2}$-alkyl, $-(CH_2)_{1-4}$-optionally substituted aryl, $-(CH_2)_{1-4}$-het; $-(CH_2)_{1-3}$-$N(R^{10})_2$; $-(CH_2)_{1-4}$-$CON(R^{10})_2$, or $-(CH_2)_{1-3}$-COOH.

14. (Original) A compound of claim 13 wherein the compound is selected from
3-Benzyl-2-(3-chloro-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;
3-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-propionic acid;
[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-acetic acid;
6-Chloro-2-(3,5-dichloro-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;
3-Bromo-5-(5-carbamimidoyl-1H-indol-2-yl)-4-hydroxy-benzamide;
2-(3,5-Dichloro-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;
3-(4-Amino-benzyl)-2-(3-bromo-2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;
2-(2-Hydroxy-biphenyl-3-yl)-1H-indole-5-carboxamidine;
2-(3-Bromo-2-hydroxy-5-nitro-phenyl)-1H-indole-5-carboxamidine;
2-(5-Hydroxy-2,3-dihydro-benzo[1,4]dioxin-6-yl)-1H-indole-5-carboxamidine;
3-Benzyl-2-(2-hydroxy-phenyl)-1H-indole-5-carboxamidine;
3-Benzyl-2-(3,5-difluoro-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;
3-Benzyl-2-(3,5-dibromo-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;
[3-Bromo-5-(5-carbamimidoyl-1H-indol-2-yl)-4-hydroxy-phenyl]-acetic acid;
3-Benzyl-2-(5-chloro-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;
2-[3-Bromo-5-(5-carbamimidoyl-1H-indol-2-yl)-4-hydroxy-phenyl]-acetamide;
2-(3,5-Difluoro-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;
2-(3,5-Dibromo-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;
2-(2-Hydroxy-5-methyl-biphenyl-3-yl)-1H-indole-5-carboxamidine;
2-(2-Hydroxy-5,4'-dimethyl-biphenyl-3-yl)-1H-indole-5-carboxamidine;
2-(3-Bromo-2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;
3-Benzyl-2-(3-bromo-2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;
3-Benzyl-2-(3-chloro-2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;
3-Benzyl-2-(2-hydroxy-3,5-dimethyl-phenyl)-1H-indole-5-carboxamidine;

2-(3,5-Dibromo-2-hydroxy-phenyl)-3-methyl-1H-indole-5-carboxamidine;
2-(2-Hydroxy-5-methyl-3-thiophen-2-yl-phenyl)-1H-indole-5-carboxamidine;
2-[2-(3-Bromo-2-hydroxy-5-methyl-phenyl)-5-carbamimidoyl-1H-indol-3-yl]-acetamide;
[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-acetic acid methyl ester;
3-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-propionic acid methyl ester;
3-(3-Amino-benzyl)-2-(3-bromo-2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;
2-(3-Bromo-2-hydroxy-5-methyl-phenyl)-3-(3-nitro-benzyl)-1H-indole-5-carboxamidine;
3-(3-Amino-benzyl)-2-(2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;
3-Benzyl-2-(3-chloro-2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;
6-Chloro-2-{5-[2-(1,1-dioxo-1-thiomorpholin-4-yl)-2-oxo-ethyl]-2-hydroxy-biphenyl-3-yl}-1H-indole-5-carboxamidine;
2-[5-(5-Carbamimidoyl-6-chloro-1H-indol-2-yl)-6-hydroxy-biphenyl-3-yl]-N-(2-piperidin-1-yl-ethyl)-acetamide;
6-Chloro-2-{2-hydroxy-5-[2-(2-methoxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl]-biphenyl-3-yl}-1H-indole-5-carboxamidine;
6-Chloro-2-{2-hydroxy-5-[2-oxo-3-(tetrahydro-furan-2-yl)-propyl]-biphenyl-3-yl}-1H-indole-5-carboxamidine;
2-[5-(5-Carbamimidoyl-6-chloro-1H-indol-2-yl)-6-hydroxy-biphenyl-3-yl]-N-(tetrahydro-furan-2-ylmethyl)-acetamide;
2-[5-(5-Carbamimidoyl-6-chloro-1H-indol-2-yl)-6-hydroxy-biphenyl-3-yl]-N-(3-methoxy-propyl)-acetamide;
Morpholine-4-carboxylic acid {2-[5-(5-carbamimidoyl-6-chloro-1H-indol-2-yl)-6-hydroxy-biphenyl-3-yloxy]-ethyl}-amide;
Phosphoric acid mono-{2-[3-(3-benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-ethyl} ester;

2-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-N-{4-[1-(1-imino-ethyl)-piperidin-4-yloxy]-phenyl}-acetamide;
4-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-butyric acid;
2-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-acetamide;
2-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-N,N-dimethyl-acetamide;
[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-acetic acid;
3-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-pentanedioic acid bis-[(2-morpholin-4-yl-ethyl)-amide];
3-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-propionamide; and
2-(3-Bromo-2-hydroxy-5-methyl-phenyl)-3-(4-nitro-benzyl)-1H-indole-5-carboxamidine;
or a stereoisomer or pharmaceutically acceptable salt form thereof.

15. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 12 or a pharmaceutically acceptable salt thereof.

16. (Currently amended): [A] The method of Claim 11 ~~for treating or preventing a thromboembolic disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to Claim 12 or a pharmaceutically acceptable salt thereof~~ wherein A represents



;

B represents



;

X represents C; and

Y represents NH.